Skip to main content

Novel MS-based strategies to Discover and Evaluate Cancer Biomarkers in urine: Application to Diagnosis of Bladder Cancer

Objective

In clinical studies, proteomics and transcriptomics allow the comparison of samples from different patients and hold special promise for the discovery of novel biomarkers and the development of “personalized medicine” approaches. Yet, translating recent discoveries into daily medical practice takes time and despite intensified researchers’ interest and investments, the rate of introduction of novel biomarkers in clinical practice is extremely disappointing. The main aim of DECanBio is to implement a strategy for protein biomarker discovery and validation relying on the use of “state of the art” mass spectrometry instrumentation for quantitative analysis of proteins. For the first time, the potential of MRM-Mass Spectrometry (MRM-MS) will be tested in the scope of a large scale validation protocol of cancer protein biomarkers. This analysis will be performed in parallel to the application of miniaturized high-throughput ELISA tests for protein quantification. DECanBio strategy will be applied to issues related to bladder cancer. Specifically, a restricted number of urinary protein biomarkers enabling the detection of recurrences during the monitoring period of patients treated for bladder tumour will be validated. The work will be performed in priority for the follow-up of low-grade superficial bladder tumours (Ta stage), which, after initial resection (without BCG therapy), are likely to evolve towards remission, recurrence, or progression to a high-grade tumor. The MRM and ELISA tests developed herein aim at the high-throughput quantification of these markers in urine. Collectively, the project has the ambition to settle a whole experimental pipe-line, from the search for new bladder cancer biomarker candidates, to their thorough evaluation and validation in clinical environment. We anticipate that the tools and knowledge that will be developed here will greatly facilitate translational studies for other diseases as well.

Field of science

  • /medical and health sciences/clinical medicine/oncology/cancer/bladder cancer
  • /natural sciences/chemical sciences/analytical chemistry/quantitative analysis
  • /natural sciences/biological sciences/biochemistry/biomolecules/proteins
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /natural sciences/biological sciences/biochemistry/biomolecules/proteins/proteomics
  • /natural sciences/chemical sciences/analytical chemistry/mass spectrometry

Call for proposal

FP7-HEALTH-2007-A
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Address
Rue Leblanc 25
75015 Paris 15
France
Activity type
Research Organisations
EU contribution
€ 615 656,33
Administrative Contact
Jérôme Garin (Dr.)

Participants (8)

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
Greece
EU contribution
€ 251 776
Address
Soranou Efesiou 4
115 27 Athina
Activity type
Research Organisations
Administrative Contact
Dimitris Raptis (Mr.)
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH

Participation ended

Switzerland
EU contribution
€ 308 959,67
Address
Raemistrasse 101
8092 Zuerich
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Bruno Domon (Dr.)
INSTITUT CURIE
France
EU contribution
€ 168 600
Address
Rue D'ulm 26
75231 Paris
Activity type
Research Organisations
Administrative Contact
Claude Huriet (Prof.)
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
France
EU contribution
€ 235 480
Address
3 Avenue Victoria
75000 Paris
Activity type
Research Organisations
Administrative Contact
Michel Bilis (Mr.)
ENTELECHON GMBH
Germany
EU contribution
€ 173 700
Address
St. Veit-weg 2
93051 Regensburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Werner Deininger (Dr.)
DIAGNOSWISS SA
Switzerland
EU contribution
€ 519 600
Address
Zi Les Ilettes Secteur 4
1870 Monthey
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Frédéric Reymond (Dr.)
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III
Spain
EU contribution
€ 234 040
Address
Calle Melchor Fernandez Almagro 3
28029 Madrid
Activity type
Research Organisations
Administrative Contact
Juan José Collazo Nieto (Mr.)
LUXEMBOURG INSTITUTE OF HEALTH
Luxembourg
EU contribution
€ 399 600
Address
Val Fleuri 84
1526 Luxembourg
Activity type
Research Organisations
Administrative Contact
Daniel Cardao (Mr.)